ALSO READImpact of US Fed's interest rate rises on China capital flows diminishing - China FX regulator China launches crackdown on illegal cosmetic surgery - paper Foreign investment is not leaving China - commerce minister US asks China to return drone seized in South China Sea China urges parties to end conflicts near China-Myanmar border
British pharmaceutical company GSK has announced it will form a strategic partnership with China's Guangzhou Institute of Respiratory Diseases (GIRD).
The strategic collaboration will focus on respiratory disease management system, including asthma and chronic obstructive pulmonary disease (COPD), GSK said on Wednesday.
According to the company, a health big data system will be developed through information sharing and covering different levels of healthcare organisations and reimbursement systems, Xinhua news agency reported.
Real world evidence (RWE) and payment evidence will be generated and provided to relative authorities for the support of health and reimbursement policy making, streamlining of clinical path management, and effective development of hierarchical medical system.
The strategic collaboration includes a prospective COPD registry study and "New Breath, Constant Care" China Asthma Patient Management Project.
The COPD registry study will cover 5,000 patients and establish an in-depth understanding of COPD disease characteristics, disease evolution, disease management, as well as evolvement of the treatment paradigm.
It is estimated that the project will cover at least 60,000 asthma patients in regular management in three years.
Respiratory diseases are recognised by the World Health Organisation as one of the four major diseases affecting people's health.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)